Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of PTC Therapeutics Inc (NASDAQ: PTCT) was $75.76 for the day, down -3.48% from the previous closing price of $78.5. In other words, the price has decreased by -$3.48 from its previous closing price. On the day, 2.49 million shares were traded. PTCT stock price reached its highest trading level at $78.655 during the session, while it also had its lowest trading level at $73.03.
Ratios:
Our analysis of PTCT’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.63. For the most recent quarter (mrq), Quick Ratio is recorded 2.26 and its Current Ratio is at 2.32.
On October 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $73.
On June 17, 2025, Truist started tracking the stock assigning a Buy rating and target price of $80.Truist initiated its Buy rating on June 17, 2025, with a $80 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 02 ’25 when Klein Matthew B. sold 3,428 shares for $79.07 per share. The transaction valued at 271,052 led to the insider holds 349,964 shares of the business.
Reeve Emma bought 733 shares of PTCT for $57,628 on Dec 03 ’25. On Dec 02 ’25, another insider, Klein Matthew B., who serves as the Officer of the company, bought 3,428 shares for $79.07 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 6082641920 and an Enterprise Value of 6867379200. As of this moment, PTC’s Price-to-Earnings (P/E) ratio for their current fiscal year is 8.86. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.42. Its current Enterprise Value per Revenue stands at 3.86 whereas that against EBITDA is 7.191.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.49, which has changed by 0.62179756 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $87.50, while it has fallen to a 52-week low of $35.95. The 50-Day Moving Average of the stock is 8.36%, while the 200-Day Moving Average is calculated to be 37.46%.
Shares Statistics:
PTCT traded an average of 1.55M shares per day over the past three months and 3206390 shares per day over the past ten days. A total of 79.93M shares are outstanding, with a floating share count of 77.16M. Insiders hold about 3.90% of the company’s shares, while institutions hold 102.96% stake in the company. Shares short for PTCT as of 1763078400 were 9418915 with a Short Ratio of 6.06, compared to 1760486400 on 7816416. Therefore, it implies a Short% of Shares Outstanding of 9418915 and a Short% of Float of 13.459999999999999.
Earnings Estimates
A comprehensive evaluation of PTC Therapeutics Inc (PTCT) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$1.09, with high estimates of -$1.03 and low estimates of -$1.14.
Analysts are recommending an EPS of between $10.66 and $5.52 for the fiscal current year, implying an average EPS of $8.82. EPS for the following year is -$0.73, with 7.0 analysts recommending between $1.25 and -$3.48.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 12 analysts. It ranges from a high estimate of $385.47M to a low estimate of $167.67M. As of. The current estimate, PTC Therapeutics Inc’s year-ago sales were $213.17MFor the next quarter, 12 analysts are estimating revenue of $194.19M. There is a high estimate of $259M for the next quarter, whereas the lowest estimate is $169M.
A total of 14 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $1.95B, while the lowest revenue estimate was $1.72B, resulting in an average revenue estimate of $1.8B. In the same quarter a year ago, actual revenue was $806.78MBased on 14 analysts’ estimates, the company’s revenue will be $971.98M in the next fiscal year. The high estimate is $1.18B and the low estimate is $804.3M.
